- A new CDC study looked at 221 patients diagnosed with multi-system inflammatory syndrome (MIS-A) in adults, which is similar to the MIS-C seen in children.
- Of the 211 patients with available data, 207 were those who had laboratory evidence of a current or previous case of COVID-19
- About half of the patients needed to be admitted to the ICU and about the same number required respiratory support
- Researchers found that 15 patients with MIS-A, or about 7%, died
A new analysis from the Centers for Disease Control and Prevention (CDC) shows that adults with the coronavirus have a 50 percent risk of developing a rare inflammatory condition often seen in children.
Researchers looked at COVID-19 patients aged 18 years and older with multi-system inflammatory syndrome (MIS-A) in adults.
They found that more than half the adults needed to be admitted to intensive care units (ICUs) and nearly as many needed respiratory support.
In addition, one in 10 MIS-A patients died.
The CDC says the findings suggest that the health of adults with MIS-A can deteriorate quickly and that doctors should be quick to treat the condition before it is too late.
A new CDC study looked at 221 patients diagnosed with Multi-System Inflammatory Syndrome (MIS-A) in adults, which is similar to the MIS-C seen in children, which resembles Kawasaki disease (file image).
About half of the MIS-A patients required admission to the ICU and about the same number required respiratory support. Image: A 39-year-old = uninfected COVID-19 patient in the ICU at St. Luke’s Boise Medical Center in Boise, Idaho, August 2021
In April 2020, doctors warned of fever, skin rash and glandular swelling in youth in Europe and the US who had been diagnosed with COVID-19.
First, the disorder, known as Pediatric Multi-System Inflammatory Syndrome (PMIS) or Multi-System Inflammatory Syndrome in Children (MIS-C), was seen only in children.
It was originally thought to be associated with Kawasaki disease, a condition that causes inflammation in the walls of blood vessels and mostly affects children under the age of five.
Cases first emerged in the UK, Italy and Spain, and started appearing in the US in May.
However, since Again, several case reports and series of a similar condition in adults known as MIS-A have been published.
for the new study published in jama network openCDC looked at 221 patients diagnosed with MIS-A worldwide between May 1, 2020 and May 25, 2021.
A total of 183 patients were from the US while the remaining 52 were from 16 other countries including Canada, France, India, Israel, South Africa, Spain, Uruguay and the UK.
Of the 211 patients with available data, the researchers found that 207 had laboratory evidence of a current or previous case of COVID-19.
The median time between the appearance of MIS-A symptoms and being diagnosed was 28 days, or four weeks.
The majority of MIS-A patients arrive at the hospital with few symptoms, the most common being a fever, with 197 or 89 percent experiencing a rise in temperature.
The next most common low blood pressure was seen in 133 patients, or 60 percent; heart disease seen in 114 patients or 51 percent; And shortness of breath was seen in 102 patients, or 46 percent.
Ten patients arrived at the hospital with Kawasaki disease.
The researchers found that 52 percent or 115 of the patients needed to be admitted to the ICU and 45 percent or 101 needed respiratory support.
Additionally, at least 15 patients — or about seven percent — died.
The CDC team has warned doctors to be on the lookout for cases of MIS-A so that patients can be identified early before the situation escalates.
The authors wrote, ‘It is important for the clinical and public health community to suspect and identify MIS-A … using diagnostic skills and to reduce the associated morbidity and mortality. to consider empirical treatment.’
‘Going forward, improving our understanding of MIS-A will require engagement in public health, translational research and health care systems. In particular, prospective research should systematically screen for MIS-A to reveal a more accurate representation of this clinical entity.
‘Currently, the best way to prevent COVID-19 and its serious consequences, including hyperinflammatory syndromes such as MIS-A, is to prevent SARS-CoV-2 infection and transmission.’